DermAb.io is developing a proprietary assay for prescribing personalized biologic therapies.

The company's noninvasive technology retrieves biomarkers painlessly from the skin’s surface in less than one minute.

DermAb.io's machine learning-based model provides the predictive value for physicians to prescribe the most effective biological medication right away.

The DermAb.io platform aims to significantly shorten the time to reach a proper treatment regimen, reducing costs and patient suffering.

This tool can save medication costs by controlling the differential costs of therapy.